New team lineup at TVM Capital
TVM Capital's Life Science Practice specializes into two dedicated teams: Healthcare Private Equity and Life Science Venture - Bernie Schuler, ex-head of healthcare buyouts at 3i, new Senior Advisor for the Healthcare Private Equity Team
Munich, 27.May 2010 - TVM Capital has regrouped its life science investment practice to better meet the increasing diversity of interesting investment opportunities in the sector. In the future, TVM Capital will operate two dedicated teams with differentiated investment concepts to invest in the development and growth of exciting pharmaceutical, biopharmaceutical, medical technologies (medtech) and healthcare services companies: Life Science Venture Capital and Healthcare Private Equity.
'We initiated the further specialization of investment sectors by establishing a Healthcare Private Equity Team. This is in response to our own strategy for the future as well as the differentiation in the needs of our investment markets', said Helmut Schühsler, Managing Partner of TVM Capital. 'This is the only way to provide best-in-class and customized equity financing solutions not only for early-stage life science venture deals, but also for growth and buyout transactions in the healthcare industry. By building dedicated teams we can offer the best possible support as a financial and strategic partner to young science and technology driven companies as well as entrepreneurial, often family-owned mature companies in the healthcare industry.'
The new Healthcare Private Equity Team invests growth capital and provides buyout financing for growth-orientated small and medium-sized enterprises (SMEs) of the pharmaceutical, diagnostic, medtech and healthcare services industries. The team is led by Christoph Schröder, who systematically positioned TVM Capital in these market segments since he rejoined the firm in 2005. Based on the team's steady deal origination work, TVM Capital has witnessed a substantial increase in high-quality investment opportunities as well as first investments. To strengthen our activities among mid-market businesses, Bernie Schuler has joined as a Senior Advisor to the Healthcare Private Equity Team. He focuses on sourcing, assessing, and structuring investments in European SMEs in the healthcare industry. Before joining TVM Capital, he was partner and head of healthcare at 3i buyouts in Frankfurt where he built and led the European dedicated healthcare team covering the partnership's global healthcare investment activities from formulation of overall investment strategy, origination and execution to asset management. As part of his role he contributed extensive and hands-on board experience in major investments with a particular focus on pharmaceuticals. Mr. Schuler also led part of an organizational change toward a sector based structure within 3i and was a member of the 3i Market Leaders Committee. Important deals he led included betapharm and Axellia Pharmaceuticals.
The Life Science Venture Team is headed by Hubert Birner and Alexandra Goll who have been responsible for some of the most successful life science venture investments at TVM Capital. Under their leadership, the TVM Life Science Venture Team will continue to focus on a multi-stage venture capital investment approach spanning discovery and development stage companies with diversified product portfolios, technology platforms, single drug development projects as well as investments in market-ready products in the pharmaceutical and medtech markets.
TVM Capital in Life Science & Healthcare
TVM Capital Life Science & Healthcare currently manages committed capital of about 860 million Euros (US $1.13bn) for investments in life science venture capital and healthcare private equity transactions from headquarters in Munich, an office in Boston and a representation in Singapore for East Asian markets. The operating entity of TVM Capital for private equity investments in the healthcare market in the Middle East and Northern Africa (MENA) is TVM Capital MENA Ltd. based in Dubai.
The TVM Capital Life Science & Healthcare Teams build on the expertise, experience, international approach and demonstrated success of 115 investments, 37 initial public offerings of portfolio companies on Nasdaq, and the London, Frankfurt, Zurich and Vienna Stock Exchanges, as well as 24 trade sales. This track record of successful investing and value creation, in traditional early and late-stage life science venture as well as healthcare private equity, make TVM Capital a preferred partner for ambitiously growing companies in the life science and healthcare industry. For more than 20 years, our business has been to invest in the growth of companies that are or aspire to be leaders in their market segment, and to be resourceful and supportive strategic partners to founders and managers alike.
For more information, please visit:
Munich, Boston, Singapore: www.tvm-capital.com
Maximilianstr. 35, Eingang C,
D- 80539 Munich, Germany
++49 (89) 998 992-0
101 Arch Street, Suite 1950
Boston, MA 02110
+1 (617) 595-8760
Maximilianstr. 35 C
80539 Munich / Germany
T +49 (89) 99 89 92 - 0
F +49 (89) 99 89 92 - 55
Follow TVM Capital on twitter: http://twitter.com/tvmcapital
Publisher Contact Information:
+49 (89) 99 89 92 - 55
Company profile of TVM Capital (Formerly Techno Venture Management )
Past press releases of TVM Capital (Formerly Techno Venture Management ).
From our Online Data Service
From our Radar
|Apr 14||€10.0M||Medical devices|
|Apr 14||€3.0M||Internet commerce|
|Apr 13||N/A||Other Software|
|Apr 13||€0.7M||Business applications|
|Apr 13||N/A||Business applications|
For information on Europe's most extensive database on technology funding click here!